Abstract
Importance: Schizophrenia is associated with increased age-related morbidity, mortality, and frailty, which are not entirely explained by behavioral factors. Prior studies using epigenetic clocks have suggested that schizophrenia is associated with accelerated aging, however these studies have primarily used unidimensional clocks that summarize aging as a single “biological age” score.
Objective: This meta-analysis uses multidimensional epigenetic clocks that split aging into multiple scores to analyze biological aging in schizophrenia. These novel clocks may provide more granular insights into the mechanistic relationships between schizophrenia, epigenetic aging, and premature morbidity and mortality.
Study selection: Selected studies included patients with schizophrenia-spectrum disorders and non- psychiatric controls with available DNA methylation data. Seven cross-sectional datasets were available for this study, with a total sample size of 1,891 patients with schizophrenia and 1,881 controls.
Data extraction and synthesis: Studies were selected by consensus Meta-analyses were performed using fixed-effect models.
Main outcomes and measures: We analyzed multidimensional epigenetic clocks, including causality- enriched CausAge clocks, physiological system-specific SystemsAge clocks, RetroelementAge, DNAmEMRAge, and multi omics-informed OMICmAge. Meta-analyses examined clock associations with schizophrenia disease status and clozapine use, after accounting for age and sex.
Results: Overall SystemsAge, CausAge, DNAmEMRAge, and OMICmAge scores demonstrated increased epigenetic aging in patients with schizophrenia after strict multiple-comparison testing. Ten of the eleven SystemsAge sub-clocks corresponding to different physiological systems demonstrated increased aging, with strongest effects for Heart and Lung followed by Metabolic and Brain systems. The causality- enriched clocks indicated increases in both damaging and adaptive aging, though these effects were weaker compared to SystemsAge scores. OMICmAge indicated changes in multiple clinical biomarkers, including hematologic and hepatic markers that support system-specific aging, as well as novel proteins and metabolites not previously linked to schizophrenia. Most clocks demonstrated age acceleration at the first psychotic episode. Notably, clozapine use was associated with increased Heart and Inflammation aging, which may partially be driven by smoking. Most results survived strict Bonferroni multiple testing correction.
Conclusions and relevance: These are the first analyses of novel multidimensional clocks in patients with schizophrenia and provide a nuanced view of aging that identifies multiple organ systems at high risk for disease in schizophrenia-related disorders.
Competing Interest Statement
A.H.C. and R. Sehgal are scientific advisors to TruDiagnostic Inc. and are named as inventors of SystemsAge which has been patented and licensed to TruDiagnostic Inc. R. Sehgal has received consulting fees from the LongevityTech.fund, Healthy Longevity Clinic and Cambrian BioPharma unrelated to this publication. J.L.S. is a scientific advisor to Precion Inc. and TruDiagnostic Inc. V.B.D. and R. Smith are employees of TruDiagnostic Inc. J.L.S., V.B.D., and R. Smith developed OMICmAge. The other authors do not declare any conflicts of interest.
Funding Statement
This work was supported by the Yale Physician Scientist Development Award (Z.M.H.) and CTSA (Z.M.H.; NIH UL1 TR001863), grants from the National Institute on Aging (A.H.C.; 1R01AG065403), the National Heart Lung Institute (J.L.S.; R01HL123915, R01HL155742, and 1R01HL169300), and the Impetus Grants (R. Sehgal). Additionally, Dr. Harvanek is a Pepper Scholar with support from the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine (P30AG021342). Dr. Higgins-Chen was supported by a Pilot Grant from the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine (P30AG021342).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GEO datasets available via NCBI.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is available on NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) and datasets are listed in Table 1. Information on clozapine status can be found in their respective papers.
